| Assessment Status | Rapid Review Complete |
| HTA ID | 25039 |
| Drug | Trastuzumab Deruxtecan |
| Brand | Enhertu® |
| Indication | Trastuzumab deruxtecan (Enhertu®) is indicated as monotherapy for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-low or HER2-ultralow breast cancer who have received at least one endocrine therapy in the metastatic setting and who are not considered suitable for endocrine therapy as the next line of treatment. |
| Assessment Process | |
| Rapid review commissioned | 13/06/2025 |
| Rapid review completed | 14/07/2025 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of trastuzumab deruxtecan compared with the current standard of care. |